Luminex Co. (LMNX) to Issue Quarterly Dividend of $0.06
Luminex Co. (NASDAQ:LMNX) declared a quarterly dividend on Thursday, December 14th, Wall Street Journal reports. Stockholders of record on Friday, December 22nd will be paid a dividend of 0.06 per share by the medical instruments supplier on Friday, January 12th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date is Thursday, December 21st.
Luminex (LMNX) opened at $20.37 on Friday. Luminex has a 12-month low of $17.68 and a 12-month high of $22.42. The company has a market cap of $904.00, a PE ratio of 35.38, a PEG ratio of 2.58 and a beta of 0.19.
Luminex (NASDAQ:LMNX) last announced its earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million during the quarter, compared to the consensus estimate of $74.38 million. Luminex had a net margin of 9.52% and a return on equity of 6.01%. Luminex’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 EPS. equities analysts anticipate that Luminex will post 0.49 earnings per share for the current year.
Several analysts recently commented on LMNX shares. Zacks Investment Research raised shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 target price for the company in a report on Thursday, August 24th. ValuEngine raised shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Jefferies Group reaffirmed a “hold” rating and set a $21.00 target price on shares of Luminex in a report on Friday, October 20th. TheStreet raised shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, BidaskClub downgraded shares of Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a strong buy rating to the company’s stock. Luminex currently has an average rating of “Hold” and an average target price of $20.00.
In other news, Director G Walter Loewenbaum II sold 39,456 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $20.40, for a total value of $804,902.40. Following the completion of the transaction, the director now directly owns 651,736 shares in the company, valued at approximately $13,295,414.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by insiders.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.